[Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways].
Ksenija ZarubinaElena N ParovichnikovaVadim SurinOlesya PshenichnikovaO A GavrilinaG A IsinovaV V TroitskayaAndrey N SokolovIrina Vladimirovna GaltsevaN M KapranovYulia O DavydovaTatiana N ObukhovaAndrey Borisovich SudarikovS M KulikovPublished in: Terapevticheskii arkhiv (2020)
NRAS,KRAS,FLT3,JAK2activating mutations do not affect the long-term results of the therapy and the rate of the negative status achievement of the minimum residual disease in patients withBCR-ABL1-negative B-ALL treated by the Russian multicenter clinical trials.
Keyphrases
- signaling pathway
- pi k akt
- clinical trial
- end stage renal disease
- wild type
- newly diagnosed
- tyrosine kinase
- acute myeloid leukemia
- peritoneal dialysis
- prognostic factors
- stem cells
- induced apoptosis
- cross sectional
- patient reported outcomes
- double blind
- mesenchymal stem cells
- study protocol
- cell therapy
- smoking cessation